Ghidurile ESC - Media Med Publicis

Ghiduri ale Societatii Europene de Cardiologie
betic subjects with and without prior myocardial infarction. N Engl J
Med 1998;339:229-234.
83. Gerstein HC, Pais P, Pogue J, Yusuf S. Relationship of glucose and insulin
levels to the risk of myocardial infarction: a case-control study. J Am
Coll Cardiol 1999;33:612-619.
84. Hu FB, Stampfer MJ, Solomon CG, Liu S, Willett WC, Speizer FE et al.
The impact of diabetes mellitus on mortality from all causes and coron
ary heart disease in women: 20 years of follow-up. Arch Intern Med
2001;161:1717-1723.
85. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for
cardiovascular disease independent of high-density lipoprotein cholesterol
level: a meta-analysis of population-based prospective studies. J Cardiovasc
Risk 1996;3:213-219.
86. Culleton BF, Larson MG, Evans JC, Wilson PW, Barrett BJ, Parfrey PS
et al. Prevalence and correlates of elevated serum creatinine levels:
the Framingham Heart Study. Arch Intern Med 1999;159:1785-1790.
87. Stamler J, Dyer AR, Shekelle RB, Neaton J, Stamler R. Relationship of
baseline major risk factors to coronary and all-cause mortality, and to
longevity: findings from long-term follow-up of Chicago cohorts. Cardiology
1993; 82:191-222.
88. Neaton JD, Blackburn H, Jacobs D, Kuller L, Lee DJ, Sherwin R et al.
Serum cholesterol level and mortality findings for men screened in the
Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention
Trial Research Group. Arch Intern Med 1992;152:1490-1500.
89. Goldbourt U, Holtzman E, Neufeld HN. Total and high density lipoprotein
cholesterol in the serum and risk of mortality: evidence of a threshold
effect. BrMedJ (Clin Res Ed) 1985;290:1239-1243.
90. Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB.
Incidence of coronary heart disease and lipoprotein cholesterol levels.
The Framingham Study. JAMA 1986;256:2835-2838.
91. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD
et al. High-density lipoprotein cholesterol and cardiovascular disease.
Four prospective American studies. Circulation 1989;79:8-15.
92. ShlipakMG, Stehman-Breen C, Vittinghoff E, Lin F, Varosy PD, Wenger NK
et al. Creatinine levels and cardiovascular events in women with heart
disease: do small changes matter? Am J Kidney Dis 2004;43:37-44.
93. Fried LF, Shlipak MG, Crump C, Bleyer AJ, Gottdiener JS, Kronmal RA
et al. Renal insufficiency as a predictor of cardiovascular outcomes and
mortality in elderly individuals. J Am Coll Cardiol 2003;41:1364-1372.
94. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum
creatinine. Nephron 1976;16:31-42.
95. Arcavi L, Behar S, Caspi A, Reshef N, Boyko V, Knobler H. High fasting
glucose levels as a predictor of worse clinical outcome in patients
with coronary artery disease: results from the Bezafibrate Infarction
Prevention (BIP) study. Am Heart J 2004; 147:239-245.
96. Muhlestein JB, Anderson JL, Horne BD, Lavasani F, Allen Maycock CA,
Bair TL et al. Effect of fasting glucose levels on mortality rate in
patients with and without diabetes mellitus and coronary artery
disease undergoing percutaneous coronary intervention. Am Heart J
2003;146:351-358.
97. Fisman EZ, Motro M, Tenenbaum A, Boyko V, Mandelzweig L, Behar S.
Impaired fasting glucose concentrations in nondiabetic patients with
ischaemic heart disease: a marker for a worse prognosis. Am Heart J
2001; 141:485-490.
98. Korpilahti K, Syvanne M, Engblom E, Hamalainen H, Puukka P, Ronnemaa T.
Components of the insulin resistance syndrome are associated with pro
gression of atherosclerosis in non-grafted arteries 5 years after coronary
artery bypass surgery. Eur Heart J 1998; 19:711-719.
99. Wilson PW, Cupples LA, Kannel WB. Is hyperglycemia associated with
cardiovascular disease? The Framingham Study. Am Heart J 1991; 121:
586-590.
100. Smith NL, Barzilay JI, Shaffer D, Savage PJ, Heckbert SR, Kuller LH et al.
Fasting and 2-hour postchallenge serum glucose measures and risk of
incident cardiovascular events in the elderly: the Cardiovascular
Health Study. Arch Intern Med 2002;162:209-216.
101. Park S, Barrett-Connor E, Wingard DL, Shan J, Edelstein S. GHb is a
better predictor of cardiovascular disease than fasting or postchallenge
plasma glucose in women without diabetes. The Rancho Bernardo Study.
Diabetes Care 1996;19:450-456.
102. Khaw KT, Wareham N, Luben R, Bingham S, Oakes S, Welch A et al.
Glycated haemoglobin, diabetes, and mortality in men in Norfolk
cohort of european prospective investigation of cancer and nutrition
(EPIC-Norfolk). BMJ2001;322:15-18.
103. Kip KE, Marroquin OC, Kelley DE, Johnson BD, Kelsey SF, Shaw LJ et al.
Clinical importance of obesity versus the metabolic syndrome in cardi
ovascular risk in women: a report from the Women's Ischemia
Syndrome Evaluation (WISE) study. Circulation 2004;109:706-713.
104. Guclu F, Ozmen B, Hekimsoy Z, Kirmaz С Effects of a statin group drug,
pravastatin, on the insulin resistance in patients with metabolic
syndrome. Biomed Pharmacother 2004;58:614-618.
105. Held C, Hjemdahl P, Rehnqvist N, Wallen NH, Bjorkander I, Eriksson SV
et al. Fibrinolytic variables and cardiovascular prognosis in patients
with stable angina pectoris treated with verapamil or metoprolol.
Results from the Angina Prognosis study in Stockholm. Circulation
1997;95:2380-2386
106. Held C, Hjemdahl P, Rehnqvist N, Bjorkander I, Forslund L, Brodin U et al.
Cardiovascular prognosis in relation to apolipoproteins and other lipid
parameters in patients with stable angina pectoris treated with verapamil or
metoprolol: results from the Angina Prognosis Study in Stockholm (APSIS).
Atherosclerosis 1997;135:109-118.
107. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma
homocysteine levels and mortality in patients with coronary artery disease. N
Engl J Med 1997; 337:230-236.
108. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative
assessment of plasma homocysteine as a risk factor for vascular disease.
Probable benefits of increasing folic acid intakes. JAMA1995;274:1049-1057.
109. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB. Production
of Creactive protein and risk of coronary events in stable and unstable angina.
European Concerted Action on Thrombosis and Disabilities Angina Pectoris
Study Group. Lancet 1997;349:462-466.
110. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC.
Hemostatic factors and the risk of myocardial infarction or sudden
death in patients with angina pectoris. European Concerted Action on
Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med
1995;332:635-641.
111. Jansson JH, Olofsson BO, Nilsson TK. Predictive value of tissue plasminogen
activator mass concentration on long-term mortality in patients with
coronary artery disease.A 7-year follow-up. Circulation1993;88:2030-2034.
112. HeldC, Hjemdahl P, Rehnqvist N, Wallen NH, Forslund L, Bjorkander I et
al. Haemostatic markers, inflammatory parameters and lipids in male
and female patients in the Angina Prognosis Study in Stockholm (APSIS).
A comparison with healthy controls. J Intern Med 1997;241:59-69.
113. Blake GJ, Ridker PM. Inflammatory bio-markers and cardiovascular risk
prediction. J Intern Med 2002;252:283-294.
114. Zebrack JS, Muhlestein JB, Horne BD, Anderson JL. C-reactive protein and
angiographic coronary artery disease: independent and additive predictors of risk in
subjects with angina. J Am Coll Cardiol 2002;39:632-637.
115. Pearson TA. New tools for coronary risk assessment: what are
their advantages and limitations? Circulation 2002;105:886-892.
116. Bogaty P BJ, Boyer L, Simard S, Joseph L, Bertrand F, Dagenais GR.
Fluctuating inflammatory markers in patients with stable ischaemic heart
disease. Arch Intern Med 2005; 165:221-226.
117. Kragelund C GB, Kober L, Hildebrandt P, Steffensen R. N-
terminal pro-B-type natriuretic peptide and long-term mortality in
stable coronary heart disease. N Engl J Med 2005;352:666-675.
118. Andreotti F, Becker FC. Atherothrombotic disorders: new insights from
hematology. Circulation 2005; 111:1855 1863.
119. Norhammar A, Malmberg K, Diderholm E, Lagerqvist B, Lindahl B, Ryden L et al.
Diabetes mellitus: the major risk factor in unstable coronary artery disease even
after consideration of the extent of coronary artery disease and benefits of
revascularization. J Am Coll Cardiol 2004;43:585-591.
120. Bartnik M, Ryden L, Ferrari R, Malmberg K, Pyorala K, Simoons M et al.
The prevalence of abnormal glucose regulation in patients with coronary
artery disease across Europe. The Euro Heart Survey on diabetes and the
heart. Eur Heart J 2004;25:1880-1890.
121. Dash H, Lipton MJ, Chatterjee K, Parmley WW. Estimation of pulmonary
artery wedge pressure from chest radiograph in patients with chronic
congestive cardiomyopathy and ischaemic cardiomyopathy. Br Heart J
1980;44:322-329.
122. Chakko S, Woska D, Martinez H, de Marchena E, Futterman L, Kessler
KM et al. Clinical, radiographic, and hemodynamic correlations in
chronic congestive heart failure: conflicting results may lead to
inappropriate care. Am JMed 1991;90:353-359.
123. Weiner DA, Ryan TJ, McCabe CH, Chaitman BR, Sheffield LT, Ferguson JC
et al. Prognostic importance of a clinical profile and exercise test in
medically treated patients with coronary artery disease. J Am Coll
Cardiol 1984;3:772-779.
124. Hammermeister KE, DeRouen TA, Dodge HT. Variables predictive of
survival in patients with coronary disease. Selection by univariate
and multivariate analyses from the clinical, electrocardiographic,
exercise,
arteriographic, and quantitative angiographic evaluations. Circulation
1979;59:421-430.
125. Witteman JC, Kok FJ, van Saase JL, Valkenburg HA. Aortic
calcification
as a predictor of cardiovascular mortality. Lancet 1986;2:1120-
53